Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metagenomi TherapeuticsMGX 10 3-1 Month Momentum % is -10.53% as of Sep. 03, 2026. GuruFocus rates MGX with a GF Score™ of 10/100 and a GF Value™ of $0.61 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, Metagenomi Therapeutics ranks worse than 58.58% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-03), Metagenomi Therapeutics's 3-1 Month Momentum % is -10.53%.
The industry rank for Metagenomi Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
MGX's 3-1 Month Momentum % is ranked worse than 58.58% of 1393
companies
in the Biotechnology industry
Industry Median: -7.27
vs MGX: -10.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Metagenomi Therapeutics 3-1 Month Momentum % Related Terms
MGX vs TVGN, VERU, GRCE: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Metagenomi Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a 3-1 Month Momentum % of -10.53% as of Sep. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #816 out of 1393 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Metagenomi Therapeutics' 3-1 Month Momentum % too high?
Metagenomi Therapeutics' current 3-1 Month Momentum % is -10.53%. Based on the distribution chart, Metagenomi Therapeutics ranks #816 out of 1393 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' 3-1 Month Momentum % compare to TVGN and VERU?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #816 out of 1393 companies for 3-1 Month Momentum %. This places Metagenomi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current 3-1 Month Momentum % is -10.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.16 — trading 90.2% above its estimated fair value. The current 3-1 Month Momentum % is -10.53%. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current 3-1 Month Momentum % is -10.53% as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metagenomi Therapeutics (MGX) Overvalued in 2026?
Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued.
The current stock price of $1.16 is trading 90.2% above its estimated GF Value™ of $0.61.
GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.
Key valuation signals for MGX:
3-1 Month Momentum %: -10.53%
GF Value™: $0.61 vs. price of $1.16 (90.2% above fair value)
No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
